House Committee Calls for CMS Action on Biosimilars

July 14, 2020Filed Under: NewsBy admin

“‘One of the ways to align these incentives would be for CMS, in particular the Center for Medicare & Medicaid Innovation, to launch a demonstration project, a shared savings program in Medicare Part B for biosimilars. This would reward physicians for increasing their utilization of biosimilars, which would both create that incentive for physicians and align that incentive with the desire of taxpayers to lower overall costs in the biologic spend category,’ [Alex Brill] said.”

Maybe Every Good Turn Deserves A Tax Break

June 12, 2020Filed Under: NewsBy admin

“The result of those changes is a 4 percent dip in total charitable giving, and, ‘for middle- to upper-middle-income tax filers, the doubling of the standard deduction is responsible for nearly all the change in giving,’ Alex Brill and Derrick Choe, both of the American Enterprise Institute, explained in a 2018 analysis.”

Shared Savings Models Could Yield Part B Savings

June 10, 2020Filed Under: NewsBy admin

“The establishment of a shared savings model has the potential to increase health care savings, biologic competition, and biosimilar utilization if implemented in Medicare Part B, according to Alex Brill, founder of Matrix Global Advisors (MGA) and a resident fellow at the American Enterprise Institute (AEI), who makes the case in a new research paper.”

Six Reasons Why Now Is A Good Time To Consider An ESOP

May 28, 2020Filed Under: NewsBy admin

“…net employment at ESOPs climbed over 60% during 2001-2011 vs. no change elsewhere, concludes research by Alex Brill, CEO of consulting firm Matrix Global Advisors.”

COVID-19 Could Cause More Than 26 Million Hospitalizations

April 23, 2020Filed Under: NewsBy admin

The COVID-19 outbreak may be as severe as the 1918 influenza pandemic that killed an estimated 675,000 people in the U.S., according to a report by consulting firm Matrix Global Advisors.

Small-Business Loan Fund May Run Dry Again. Is There Another Way?

April 22, 2020Filed Under: NewsBy admin

“‘That could help accelerate the rebound if we can just kind of mothball the economy and then turn back on the same economy with the same manager-employee relationship,” said Alex Brill, a resident fellow at the right-leaning American Enterprise Institute.”

Teva Fights Muddy Reputation With Positive Report

January 23, 2020Filed Under: NewsBy admin

“The main conclusion of Brill’s report is that Teva makes a significant contribution to the economies of the countries where it operates, via both direct and indirect employment.”

New Belgium Brewery’s employees think like owners. Because they are.

October 18, 2019Filed Under: NewsBy admin

Alex Brill was quoted in Fast Company for his research on tax policy effects on business:

“… [Brill] has found that employees in ESOPs “get better at the job, and instead of quitting as soon as they get skills, they stay and get more skills.” Companies with ESOPs require fewer managers, as AEI’s Brill discovered in his research, because workers are given more freedom and are better able to manage themselves.”

Employers Could Reap Substantial Savings Through Biosimilars, But Not Without Targeted Effort

August 23, 2019Filed Under: NewsBy admin

“A new report from Matrix Global Advisors and the National Business Group on Health, sponsored by Boehringer Ingelheim, shows that employers could see substantial savings from biosimilars, but those savings won’t come without a concerted effort to encourage biosimilar use.”

Debate Over Whether Biologics Constitute Natural Monopolies Continues

August 1, 2019Filed Under: NewsBy admin

“Peter B. Bach, MD, a well-known critic of high drug prices, along with Jennifer A. Ohn, MPH, Preston Atteberry, MD, and Mark Trusheim, MSc, first wrote in April that biosimilar competition is an economically inefficient way to achieve the goal of lower prices; the biosimilar environment is different than the one that exists in the generic marketplace for small-molecule drugs. These authors said, instead, that biosimilars are natural monopolies and as such need price regulation in order for them to succeed and for prices to come down.”